Alzamend Neuro Receives Nasdaq Non-Compliance Notice for Equity Deficiency

summarizeSummary

Alzamend Neuro received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement, initiating a compliance period to avoid potential delisting.

check_boxKey Events

• Nasdaq Non-Compliance Notice Received

  Alzamend Neuro received a letter from Nasdaq on March 20, 2026, indicating non-compliance with the minimum stockholders' equity requirement.

• Equity Below Listing Standard

  The company's stockholders' equity was approximately $2.2 million as of January 31, 2026, falling below Nasdaq's Rule 5550(b)(1) minimum of $2.5 million.

• Compliance Plan Required

  Alzamend Neuro has 45 calendar days, until May 4, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days (until September 16, 2026) to demonstrate compliance.

• Potential Delisting Risk

  Failure to regain compliance could lead to delisting from The Nasdaq Capital Market, though the company retains the right to appeal such a decision.

auto_awesomeAnalysis

Alzamend Neuro, a nano-cap biotech, has received a critical notice from Nasdaq for failing to meet the minimum stockholders' equity requirement. This is a significant event as continued listing on Nasdaq is crucial for liquidity and investor confidence, especially for a company in the clinical trial stage. The company's reported equity of $2.2 million falls short of the $2.5 million threshold, indicating financial fragility. While there is a compliance period, the need to raise additional equity adds pressure, particularly following the recent establishment of a $3 million At-The-Market (ATM) offering on March 6, 2026. The success of this ATM program or other capital-raising efforts will be vital for the company to regain compliance and avoid potential delisting.